The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | A Phase I study of WVT078, a BCMA×CD3 bsAb, with a gamma-secretase inhibitor (WHG626) in R/R MM
Fredrik Schjesvold, MD, PhD, Oslo University Hospital, Oslo, Norway, discusses the early results of a Phase I dose-escalation study (NCT04123418) of WVT078, a BCMAxCD3 bispecific antibody (bsAb), combined with the gamma-secretase (GS) inhibitor WHG626, in patients with relapsed/refractory (R/R) multiple myeloma (MM). Pre-clinical in vitro investigations found that WHG626 enhanced the anti-myeloma activity of WVT078, likely by eliminating the shedding of soluble BCMA from MM cells to prevent it from interfering with BCMA-targeting agents, and pharmacodynamic biomarker analysis from this Phase I study confirmed this mechanism of action. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria for lectures and educational material: Skylite DX, Schain, Novartis, Janssen-Cilag, Takeda, Pfizer, Oncopeptides, Amgen, Sanofi, Bristol Myers Squibb, Daiichi Sankyo, Celgene, GlaxoSmithKline, Abbvie
Consultancy: Janssen-Cilag, Takeda, Oncopeptides, Sanofi, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Abbvie
Research Funding: Janssen-Cilag, Oncopeptides, Sanofi, Targovax, Celgene, GlaxoSmithKline
